Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
3,705 stopped studies mapped to Carcinoma and descendants · 91% state a reason
Over the 3,705 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02297425 | A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer | Phase 2 | withdrawn | Nov 21, 2014 | Pfizer | not stated | Not stated |
| NCT00511576 | Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for… | Phase 1 | terminated | Aug 6, 2007 | Mirati Therapeutics Inc. | Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All… | Other (stated, no rule matched) |
| NCT00975767 | A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced… | Phase 1 | terminated | Sep 11, 2009 | Mirati Therapeutics Inc. | The study was terminated due to a need for a reformulation of the study drug. Phase 1 completed, no… | Enrollment / accrual |
| NCT01492920 | Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With… | Phase 3 | withdrawn | Dec 15, 2011 | Gynecologic Oncology Group | Withdrawn | Other (stated, no rule matched) |
| NCT00352859 | Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib | Phase 4 | terminated | Jul 17, 2006 | Bayer | not stated | Not stated |
| NCT00072137 | Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who… | Phase 1 | terminated | Nov 6, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01761747 | Ponatinib for Squamous Cell Lung and Head and Neck Cancers | Phase 2 / Phase 3 | terminated | Jan 7, 2013 | Dana-Farber Cancer Institute | FDA hold and toxicity associated with study drug | Safety / toxicity |
| NCT01927393 | Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV… | N/A | withdrawn | Aug 22, 2013 | City of Hope Medical Center | Study was not funded | Funding |
| NCT00622479 | Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia. | Phase 1 | terminated | Feb 25, 2008 | Bayer | not stated | Not stated |
| NCT01336543 | Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III… | Phase 2 | withdrawn | Apr 18, 2011 | Syed Jafri | Low accrual, small patient population at center. | Enrollment / accrual |
| NCT00452075 | Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for… | Phase 2 | terminated | Mar 26, 2007 | Rigshospitalet, Denmark | Poor recruitment | Enrollment / accrual |
| NCT00678288 | A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following… | Phase 2 | terminated | May 15, 2008 | Bayer | not stated | Not stated |
| NCT01664663 | Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis…(PLANET) | Phase 2 | terminated | Aug 14, 2012 | Ass. Prof. Jan Nyman | Safety analysis showed increased grade 5 toxicity in experimental arm. | Safety / toxicity |
| NCT01838265 | Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without…(MGM) | — | withdrawn | Apr 24, 2013 | University of Miami | Unlikely to Accrue | Enrollment / accrual |
| NCT01038037 | First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer(Lung-TRIO) | Phase 2 | terminated | Dec 23, 2009 | Vejle Hospital | 1. Very low enrollment rate. 2. Recent studies question the effect of adding panitumumab in this… | Safety / toxicity |
| NCT01666431 | Single-center Investigator Initiated Pilot Study Investigating the Tumor Response of… | Phase 2 | terminated | Aug 16, 2012 | University of Zurich | not stated | Not stated |
| NCT02070419 | TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer | Phase 2 | withdrawn | Feb 25, 2014 | Case Comprehensive Cancer Center | Principal Investigator left institution | Investigator |
| NCT00549328 | Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer | Phase 2 | terminated | Oct 25, 2007 | GlaxoSmithKline | Study enrolment was delayed in starting and too slow to support further development in this setting | Enrollment / accrual |
| NCT01465815 | Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous… | Phase 1 / Phase 2 | withdrawn | Nov 7, 2011 | OHSU Knight Cancer Institute | Drug manufacturer, Astellas Pharma, informed us that safety and efficacy of Erlotinib and OSI-906… | Safety / toxicity |
| NCT01799161 | Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients… | Phase 1 | withdrawn | Feb 26, 2013 | Eckhard Podack | Insufficient funding | Funding |
| NCT01254734 | Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck… | N/A | terminated | Dec 7, 2010 | City of Hope Medical Center | The study will be rewritten as a data registry study | Other (stated, no rule matched) |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or… | Phase 1 | terminated | Mar 17, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00300885 | A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel… | Phase 3 | terminated | Mar 10, 2006 | Bayer | Based on the results of the interim analysis, it was determined that the study would not meet its… | Efficacy / futility |
| NCT01748851 | XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC) | Phase 3 | terminated | Dec 13, 2012 | Dong-A University Hospital | Poor enrollment of patients | Enrollment / accrual |
| NCT00108186 | Celecoxib Treatment for Lung Cancer | Phase 1 | withdrawn | Apr 15, 2005 | US Department of Veterans Affairs | Couldn't accrue patients | Enrollment / accrual |
| NCT01313663 | A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in… | Phase 2 | terminated | Mar 14, 2011 | GlaxoSmithKline | not stated | Not stated |
| NCT00808145 | Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC) | Phase 2 | withdrawn | Dec 15, 2008 | Lahey Clinic | Lack of enrollment, many screen failures and non eligible study participants | Enrollment / accrual |
| NCT01791998 | Magnetic Resonance Thermal Image Guided Laser Interstitial Thermal Therapy in Treating… | N/A | withdrawn | Feb 15, 2013 | University of Chicago | Funding was time sensitive and expired. No subjects enrolled. | Enrollment / accrual |
| NCT01020305 | Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | terminated | Nov 25, 2009 | Sandy Srinivas | Decision by funding sponsor due to poor accrual | Enrollment / accrual |
| NCT01939483 | A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases | N/A | withdrawn | Sep 11, 2013 | University of California, Irvine | Slow accrual | Enrollment / accrual |
| NCT02254044 | Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell… | Phase 1 | terminated | Oct 1, 2014 | Boehringer Ingelheim | not stated | Not stated |
| NCT00982696 | Treatment of Advanced Head and Neck Cancer | Phase 2 | terminated | Sep 23, 2009 | Milton S. Hershey Medical Center | Deemed ineffective | Other (stated, no rule matched) |
| NCT01095367 | Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of… | N/A | terminated | Mar 30, 2010 | University of British Columbia | due to company changes and lack of funding-unlikely to have sufficient numbers to analyze… | Funding |
| NCT00892242 | Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer | Phase 1 | terminated | May 4, 2009 | Washington University School of Medicine | Principal Investigator decided to close the study early. | Investigator |
| NCT01049776 | GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line | Phase 2 | terminated | Jan 14, 2010 | Illinois CancerCare, P.C. | Study was terminated due to positive results seen in statistical analysis. Adequate patient… | Enrollment / accrual |
| NCT02127372 | Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571 | Phase 1 / Phase 2 | terminated | Apr 30, 2014 | Duke University | The study was closed due to poor accrual | Enrollment / accrual |
| NCT01943058 | Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients… | Phase 2 | withdrawn | Sep 16, 2013 | University of Southern California | Lack of funding | Funding |
| NCT01859182 | Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced… | Phase 2 | withdrawn | May 21, 2013 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01872988 | Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related… | Phase 3 | terminated | Jun 7, 2013 | Taichung Veterans General Hospital | Difficult in patient enrollment | Enrollment / accrual |
| NCT01718223 | Photodynamic Therapy Using Temoporfin Before Surgery in Treating Patients With Recurrent… | N/A | withdrawn | Oct 31, 2012 | Roswell Park Cancer Institute | implementation issues | Other (stated, no rule matched) |
| NCT01305772 | Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated…(TOP0901) | Phase 2 | terminated | Mar 1, 2011 | Neal Ready | This study was terminated for low accrual. | Enrollment / accrual |
| NCT00509366 | Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV…(TOP0602) | Phase 2 | terminated | Jul 31, 2007 | Duke University | Study terminated due to reproducibility issues with genomics prediction model. | Other (stated, no rule matched) |
| NCT01682031 | Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck… | Phase 2 | terminated | Sep 10, 2012 | Roswell Park Cancer Institute | Due to a lack of funding | Funding |
| NCT01403259 | SOX as Salvage Treatment in Nasopharyngeal Carcinoma | Phase 2 | terminated | Jul 27, 2011 | Fudan University | poor accrual of eligible patients | Enrollment / accrual |
| NCT01175499 | Concordance of Two Endoscopic Procedures for Diagnosis of Carcinoma of the Upper…(TNFE-NBI) | N/A | withdrawn | Aug 4, 2010 | University of California, San Francisco | Unable to obtain funding to continue recruitment; no accrual | Enrollment / accrual |
| NCT00911326 | Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma | Phase 3 | terminated | Jun 1, 2009 | Navidea Biopharmaceuticals | The trial was terminated early based on an interim review by the Data and Safety Monitoring… | Safety / toxicity |
| NCT02209727 | Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic… | Phase 1 | terminated | Aug 6, 2014 | Boehringer Ingelheim | not stated | Not stated |
| NCT00787852 | A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung… | Phase 1 | terminated | Nov 10, 2008 | Brown University | for efficacy and safety reasons | Safety / toxicity |
| NCT01938456 | Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects… | Phase 1 | withdrawn | Sep 10, 2013 | GlaxoSmithKline | This study was Cancelled Before Active | Other (stated, no rule matched) |
| NCT00001703 | Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With… | Phase 2 | terminated | Nov 4, 1999 | National Cancer Institute (NCI) | Due to poor accrual and lack of peptide vaccine | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Jan 12, 2015source: clinicaltrials